Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Brodalumab Biologics Sequence Review Report 2026: IL-17RA Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brodalumab, an antibody targeting IL-17RA.
6 min read
Ixekizumab Biologics Sequence Review Report 2026: IL-17A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ixekizumab, an antibody targeting IL-17A.
6 min read
Secukinumab Biologics Sequence Review Report 2026: IL-17A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Secukinumab, an antibody targeting IL-17A.
6 min read
Brazikumab Biologics Sequence Review Report 2026: IL-23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brazikumab, an antibody targeting IL-23.
6 min read
Mirikizumab Biologics Sequence Review Report 2026: IL-23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mirikizumab, an antibody targeting IL-23.
6 min read
Tildrakizumab Biologics Sequence Review Report 2026: IL-23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tildrakizumab, an antibody targeting IL-23.
6 min read
Risankizumab Biologics Sequence Review Report 2026: IL-23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Risankizumab, an antibody targeting IL-23.
6 min read
Guselkumab Biologics Sequence Review Report 2026: IL-23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Guselkumab, an antibody targeting IL-23.
6 min read
Ustekinumab Biologics Sequence Review Report 2026: IL-12/IL-23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ustekinumab, an antibody targeting IL-12/IL-23.
6 min read
Suptavumab Biologics Sequence Review Report 2026: RSV F protein Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suptavumab, an antibody targeting RSV F protein.
6 min read
Golimumab Biologics Sequence Review Report 2026: TNF Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Golimumab, an antibody targeting TNF.
6 min read
Infliximab Biologics Sequence Review Report 2026: TNF Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Infliximab, an antibody targeting TNF.